Last reviewed · How we verify
Lurasidone tablets
Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain.
Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain. Used for Schizophrenia, Bipolar I disorder depression, Major depressive disorder (adjunctive treatment).
At a glance
| Generic name | Lurasidone tablets |
|---|---|
| Also known as | LATUDA |
| Sponsor | Sumitomo Pharma (Suzhou) Co., Ltd. |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT7 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Lurasidone acts as an antagonist at dopamine D2 receptors and serotonin 5-HT7 receptors, with high binding affinity and selectivity for these targets. This dual antagonism helps modulate neurotransmitter activity implicated in psychotic and mood disorders. The drug has minimal affinity for other receptors, which may contribute to a favorable side-effect profile compared to first-generation antipsychotics.
Approved indications
- Schizophrenia
- Bipolar I disorder depression
- Major depressive disorder (adjunctive treatment)
Common side effects
- Akathisia
- Somnolence
- Parkinsonism
- Nausea
- Agitation
- Headache
Key clinical trials
- A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia (PHASE3)
- Chinese Longitudinal and Systematic Study of Bioplar Disorder (NA)
- A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007) (PHASE1)
- MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003) (PHASE1)
- A Study of Lurasidone HCl in Subjects With Schizophrenia (PHASE4)
- A Clinical Trial of Lurasidone in Treatment of Schizophrenia (PHASE3)
- Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old (PHASE4)
- Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lurasidone tablets CI brief — competitive landscape report
- Lurasidone tablets updates RSS · CI watch RSS
- Sumitomo Pharma (Suzhou) Co., Ltd. portfolio CI